A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.
about
Polyamines and cancer: implications for chemotherapy and chemopreventionIn vitro human cell line models to predict clinical response to anticancer drugsAn ensemble based top performing approach for NCI-DREAM drug sensitivity prediction challengeA community effort to assess and improve drug sensitivity prediction algorithms.Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatmentInitial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast CancerSubtype and pathway specific responses to anticancer compounds in breast cancer.Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers.Biochemical evaluation of the anticancer potential of the polyamine-based nanocarrier Nano11047Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism.Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
P2860
Q26864516-2453C2C8-05F2-4F9D-8847-5D981742536BQ27000665-D9560D63-9614-4BB2-B2DE-735A6E359B83Q28540186-FC003348-5CCE-4A09-8A7A-B76C69BCBCF7Q30371323-0E99DF80-BBD0-4E3F-BF78-6343F33E1830Q30436867-D630F555-30D6-4A26-99D7-47BA2A2F48F4Q33517983-8D3751EF-569A-4C26-9918-DDE6469A9852Q34632169-4A4F4BD5-3813-490E-8E86-42CE3631C6BCQ35046326-844088BB-0593-4834-A954-4E45983994A0Q35693389-A7A9887C-09B0-4FA4-9566-8FB1438B396AQ35779241-4EE94462-A616-448F-BB9D-B60F900D8F31Q36058024-DA388981-2BFB-4DEC-9DA0-E87305A22258Q36351012-904F3982-9772-42A7-B646-DE62EA1CE26FQ37149249-C46A6565-15B5-4A41-A242-CB5EECEFD63AQ37254835-EC4718E6-FC43-4A87-AD45-CDFBE35F8848Q37605645-5CE9C22A-9AF9-4B3C-AA51-5BC8A4AA5BC0Q47111961-91CAA7B8-1EBE-4809-89D3-5B99D93221FCQ53078543-9AFA0CE8-8E1A-4B3F-B985-F2784E2CB5E2
P2860
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@ast
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@en
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@nl
type
label
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@ast
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@en
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@nl
prefLabel
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@ast
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@en
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@nl
P2093
P2860
P356
P1433
P1476
A systems analysis of the chem ...... e polyamine analogue PG-11047.
@en
P2093
Andrew J Wyrobek
Debopriya Das
Gerald V Fontenay
Heidi S Feiler
Joe W Gray
Laura M Heiser
Laurence J Marton
Nicholas J Wang
Nora Bayani
Paul T Spellman
P2860
P2888
P356
10.1186/1741-7015-7-77
P407
P577
2009-12-14T00:00:00Z
P5875
P6179
1036660913